Full Text
HPR31 Is the UK’S Ilap Process Delivering Its Intended Benefits? a Review of Access to Orbis Designated Oncology Products within the UK

Abstract

Authors

J. Gaultney K. McDonald S. Mushtaq

Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×